Impax Laboratories Company Profile (NASDAQ:IPXL)

Impax Laboratories trades on the NASDAQ under the ticker symbol "IPXL."

Impax Laboratories, Inc. (NASDAQ:IPXL) released its quarterly earnings results on Wednesday, August, 9th. The company reported $0.18 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $0.14 by $0.04. The business earned $202.08 million during the quarter, compared to analyst estimates of $195.62 million. Impax Laboratories had a negative net margin of 71.08% and a positive return on equity of 9.05%. The company's quarterly revenue was up 17.1% on a year-over-year basis. During the same period in the prior year, the firm posted $0.21 earnings per share. View Impax Laboratories' Earnings History.

Impax Laboratories is scheduled to release their next quarterly earnings announcement on Thursday, November, 9th 2017. View Earnings Estimates for Impax Laboratories.

Impax Laboratories updated its FY17 earnings guidance on Wednesday, August, 9th. The company provided earnings per share guidance of $0.55-0.70 for the period, compared to the Thomson Reuters consensus estimate of $0.66.

15 brokerages have issued 12-month price targets for Impax Laboratories' shares. Their predictions range from $10.00 to $27.00. On average, they anticipate Impax Laboratories' share price to reach $19.67 in the next twelve months. View Analyst Ratings for Impax Laboratories.

Here are some recent quotes from research analysts about Impax Laboratories stock:

• 1. According to Zacks Investment Research, "Impax’s Generics segment is facing competitive and pricing pressure, which is expected to persist through 2017. However, epinephrine auto-injector sales have picked up The company is taking steps to reduce costs and improve efficiencies, which may save an estimated $130 million by the end of 2019. Moreover, the company’s manufacturing facilities have been hampered by quality control issues since 2011, which delayed Rytary’s approval. The merger with Amneal Pharma is a positive for Impax as it will have a diverse pipeline with more than 300 products under review or late stage development. However, the generics market is highly crowded and Impax faces stiff competition from other major companies. Impax’s shares have outperformed the industry so far this year. Estimates have remained stable ahead of the Q3 earnings results. The company has a mixed record of earnings surprises in recent quarters." (10/20/2017)
• 2. Cantor Fitzgerald analysts commented, "We hosted our annual Cantor Fitzgerald Healthcare Conference in New York today, with IPXL in attendance." (9/25/2017)
• 3. Guggenheim analysts commented, "Impax (IPXL, BUY, $12.70) named Paul Bisaro as its new, full-time CEO earlier today, which increases our confidence that there could be upside to consensus expectations in '17+. Bisaro has 25 years of generic and branded pharma experience, with an impressive track record of execution and transformation at companies like Allergan (AGN, NEUTRAL, $237.33) and its predecessors and Barr Pharmaceuticals (acquired by TEVA [BUY, $32.76] in 2010). Bisaro is also on the Board of Directors of AGN and Zoetis (ZTS, BUY, $53.85)." (3/27/2017)
• 4. Royal Bank Of Canada analysts commented, "The stock was down -35% following IPXL's 4Q results and first-time 2017 update (no revenue or EPS given, as expected). We continue to see a number of generic headwinds that will linger as IPXL pursues a leadership change and what we see as needed review of strategic positioning. We lower EPS and target to reflect continued challenges. Remain Sector Perform." (3/2/2017)

Some companies that are related to Impax Laboratories include BTG plc (BTG), Hikma Pharmaceuticals Plc (HIK), Horizon Pharma PLC (HZNP), Amicus Therapeutics (FOLD), Corcept Therapeutics Incorporated (CORT), Theravance Biopharma (TBPH), Cambrex Corporation (CBM), Emergent Biosolutions (EBS), Innoviva (INVA), Pacira Pharmaceuticals (PCRX), Akcea Therapeutics (AKCA), Lannett Co (LCI), Amphastar Pharmaceuticals (AMPH), SciClone Pharmaceuticals (SCLN), AMAG Pharmaceuticals (AMAG), Corium International (CORI), Collegium Pharmaceutical (COLL) and Teligent (TLGT).

Impax Laboratories' management team includes the folowing people:

• Robert L. Burr, Independent Chairman of the Board
• Paul M. Bisaro, President, Chief Executive Officer, Director
• Bryan M. Reasons, Chief Financial Officer, Senior Vice President - Finance
• Douglas S. Boothe, President - Generics Division
• Michael J. Nestor, President - Impax Specialty Pharmaceutical Division
• Mark A. Schlossberg Esq., Senior Vice President, General Counsel, Corporate Secretary
• Jeffrey D. Nornhold, Senior Vice President - Technical Operations
• J. Kevin Buchi, Director
• Janet S. Vergis, Director
• Leslie Z. Benet Ph.D., Independent Director

Impax Laboratories' stock is owned by a variety of of institutional and retail investors. Top institutional investors include SHANGHAI FOSUN PHARMACEUTICAL (GROUP) COMPANY ., LTD. (5.19%) and Fisher Asset Management LLC (2.08%). Company insiders that own Impax Laboratories stock include Leslie Z Benet and Michael Nestor. View Institutional Ownership Trends for Impax Laboratories.

Impax Laboratories' stock was bought by a variety of institutional investors in the last quarter, including Fisher Asset Management LLC. View Insider Buying and Selling for Impax Laboratories.

Shares of Impax Laboratories can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Impax Laboratories stock can currently be purchased for approximately $21.25.